TrialsgrambetaRCTs are beautiful

DAPA-HF

2019

Dapagliflozin and Prevention of Adverse outcomes in Heart Failure

In 4,744 patients with HFrEF (with or without diabetes), dapagliflozin reduced worsening HF or CV death versus placebo.

Result

Efficacy: Worsening HF or CV deathHR 0.74

Below 1 favours dapagliflozin, above 1 favours placebo.

Event rates
Absolute difference
4.9 points

The absolute difference is derived from the event rates.

Also reported: Benefit independent of diabetes.

Original publication
Subtopic
SGLT2 inhibitors
Design
Double-blind RCT, median 18 mo
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
McMurray JJV, et al. N Engl J Med. 2019;381(21):1995-2008.doi 10.1056/NEJMoa1911303

Discussion & critique

Defined SGLT2i as a fourth GDMT pillar. EMPEROR-Reduced confirmed class effect. Dapagliflozin/empagliflozin now standard regardless of diabetes status.

Discussed in podcasts